AI Engines For more Details: Perplexity Kagi Labs You
Liver Diseases: TUDCA has hepatoprotective properties and is primarily used to treat liver diseases. It has been shown to reduce liver damage, inflammation, and apoptosis (cell death) in conditions such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), cholestasis, and liver fibrosis. TUDCA may help improve liver function and promote liver regeneration by inhibiting ER stress and mitochondrial dysfunction.
Biliary Disorders: TUDCA is used to dissolve gallstones in patients who cannot undergo surgery. It can help dissolve cholesterol gallstones by reducing the secretion of cholesterol into bile and promoting the solubilization of cholesterol crystals. TUDCA may also improve bile flow and reduce bile duct inflammation in conditions such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Endoplasmic Reticulum (ER) Stress: TUDCA is a potent inhibitor of endoplasmic reticulum (ER) stress, which occurs when unfolded or misfolded proteins accumulate in the ER lumen. ER stress is implicated in the pathogenesis of various diseases, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease), diabetes, and inflammatory conditions. TUDCA can alleviate ER stress by stabilizing protein folding and reducing the unfolded protein response (UPR), thereby protecting cells from apoptosis and promoting cell survival.
Neurological Disorders: TUDCA has neuroprotective properties and has been investigated for its potential therapeutic effects in neurological disorders. It can cross the blood-brain barrier and exert antioxidant, anti-inflammatory, and anti-apoptotic effects in the central nervous system. TUDCA may help protect neurons, improve synaptic function, and reduce neuroinflammation in conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and ischemic stroke.
Metabolic Disorders: TUDCA has been studied for its potential benefits in metabolic disorders such as obesity, insulin resistance, and type 2 diabetes. It can improve insulin sensitivity, glucose metabolism, and lipid profile by reducing ER stress, inflammation, and oxidative stress in metabolic tissues such as the liver, adipose tissue, and skeletal muscle. TUDCA may help mitigate metabolic dysfunction and prevent the progression of metabolic syndrome and related complications.
Gastrointestinal Disorders: TUDCA has been investigated for its potential therapeutic effects in gastrointestinal disorders such as inflammatory bowel disease (IBD) and colitis. It can reduce intestinal inflammation, epithelial damage, and mucosal injury by inhibiting inflammatory signaling pathways and promoting mucosal healing. TUDCA may help alleviate symptoms and improve disease outcomes in patients with IBD and other gastrointestinal conditions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Increases |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium animalis | Reduces |
| species | Bifidobacterium bifidum | Reduces |
| species | Bifidobacterium breve | Reduces |
| species | Bifidobacterium catenulatum | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Bifidobacterium pseudocatenulatum | Reduces |
| species | Bifidobacterium pseudolongum | Reduces |
| species | Faecalibacterium prausnitzii | Increases |
| species | Parabacteroides distasonis | Increases |
| species | Parabacteroides goldsteinii | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 2.4 | 1.1 | 1.18 |
| ADHD | 3.8 | 1.1 | 2.45 |
| Age-Related Macular Degeneration and Glaucoma | 0.8 | 0.8 | |
| Allergic Rhinitis (Hay Fever) | 2 | 2.6 | -0.3 |
| Allergies | 5.3 | 3.6 | 0.47 |
| Allergy to milk products | 1.1 | 2.9 | -1.64 |
| Alopecia (Hair Loss) | 0.6 | 1.1 | -0.83 |
| Alzheimer's disease | 4.1 | 4.2 | -0.02 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 1.5 | 0.27 |
| Ankylosing spondylitis | 1.8 | 1.4 | 0.29 |
| Anorexia Nervosa | 2.1 | 1.9 | 0.11 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 5.2 | 1.8 | 1.89 |
| Atherosclerosis | 2.2 | 1.1 | 1 |
| Atrial fibrillation | 2.4 | 2.2 | 0.09 |
| Autism | 6.3 | 6 | 0.05 |
| Autoimmune Disease | 1.1 | 0.5 | 1.2 |
| Barrett esophagus cancer | 0.5 | 0.5 | |
| benign prostatic hyperplasia | 0.8 | 0.5 | 0.6 |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 1.7 | 2.3 | -0.35 |
| Brain Trauma | 1.6 | 1 | 0.6 |
| Cancer (General) | 1 | 1.3 | -0.3 |
| Carcinoma | 1.6 | 1.6 | 0 |
| Celiac Disease | 4.4 | 1.6 | 1.75 |
| Cerebral Palsy | 1.6 | 0.9 | 0.78 |
| Chronic Fatigue Syndrome | 4.1 | 1 | 3.1 |
| Chronic Kidney Disease | 3.1 | 0.6 | 4.17 |
| Chronic Lyme | 0.5 | 0.5 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.5 | 0.4 |
| Chronic Urticaria (Hives) | 2.2 | 0.2 | 10 |
| Coagulation / Micro clot triggering bacteria | 1.1 | -1.1 | |
| Cognitive Function | 1.9 | 2.3 | -0.21 |
| Colorectal Cancer | 2.1 | 5 | -1.38 |
| Constipation | 2.5 | 0.8 | 2.13 |
| Coronary artery disease | 1.1 | 0.7 | 0.57 |
| COVID-19 | 7.1 | 6.2 | 0.15 |
| Crohn's Disease | 5.8 | 4.1 | 0.41 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 0.8 | 1.2 | -0.5 |
| deep vein thrombosis | 1.3 | 0.9 | 0.44 |
| Denture Wearers Oral Shifts | 0 | 0 | |
| Depression | 8.9 | 5.9 | 0.51 |
| Dermatomyositis | 1.1 | 0.5 | 1.2 |
| Eczema | 0.4 | 2 | -4 |
| Endometriosis | 1.5 | 2.5 | -0.67 |
| Eosinophilic Esophagitis | 1.6 | 1.6 | |
| Epilepsy | 4.7 | 3.1 | 0.52 |
| erectile dysfunction | 0.7 | 0.6 | 0.17 |
| Fibromyalgia | 1.6 | 2 | -0.25 |
| Functional constipation / chronic idiopathic constipation | 5.3 | 4.4 | 0.2 |
| gallstone disease (gsd) | 1.7 | 1.7 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 1.1 | 0.09 |
| Generalized anxiety disorder | 2 | 3.2 | -0.6 |
| Glioblastoma | 0.8 | 0.8 | |
| Gout | 1.4 | 0.6 | 1.33 |
| Graves' disease | 2.6 | 2.7 | -0.04 |
| Gulf War Syndrome | 1.8 | 1.5 | 0.2 |
| Halitosis | 0.5 | 0.5 | |
| Hashimoto's thyroiditis | 2.7 | 1.6 | 0.69 |
| Heart Failure | 3.6 | 2.2 | 0.64 |
| hemorrhagic stroke | 0.5 | 0.6 | -0.2 |
| Hidradenitis Suppurativa | 1.1 | 1.1 | |
| High Histamine/low DAO | 0.6 | 0.5 | 0.2 |
| hypercholesterolemia (High Cholesterol) | 1.2 | 1.2 | |
| hyperglycemia | 2.1 | 2.8 | -0.33 |
| Hyperlipidemia (High Blood Fats) | 2.2 | 0.4 | 4.5 |
| hypersomnia | 0 | 0 | |
| hypertension (High Blood Pressure | 3.3 | 4.1 | -0.24 |
| Hypothyroidism | 0.8 | 1.1 | -0.38 |
| Hypoxia | 1.3 | 1.5 | -0.15 |
| IgA nephropathy (IgAN) | 0.5 | 2 | -3 |
| Inflammatory Bowel Disease | 6.1 | 5 | 0.22 |
| Insomnia | 3 | 1.5 | 1 |
| Intelligence | 1.2 | 0.2 | 5 |
| Intracranial aneurysms | 2.1 | 1.5 | 0.4 |
| Irritable Bowel Syndrome | 6.1 | 3.8 | 0.61 |
| ischemic stroke | 3.4 | 2.1 | 0.62 |
| Juvenile idiopathic arthritis | 0.6 | 0.6 | |
| Liver Cirrhosis | 4.5 | 2.6 | 0.73 |
| Long COVID | 6.7 | 3.9 | 0.72 |
| Low bone mineral density | 0.2 | 0.2 | |
| Lung Cancer | 2.5 | 2.5 | |
| Mast Cell Issues / mastitis | 0.5 | 1.6 | -2.2 |
| ME/CFS with IBS | 1.1 | 1 | 0.1 |
| ME/CFS without IBS | 0.4 | 1 | -1.5 |
| Menopause | 1.9 | 0 | 0 |
| Metabolic Syndrome | 6.6 | 4.4 | 0.5 |
| Mood Disorders | 7.7 | 8.1 | -0.05 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.4 | 0.25 |
| Multiple Sclerosis | 4.2 | 3.6 | 0.17 |
| Multiple system atrophy (MSA) | 1.6 | -1.6 | |
| myasthenia gravis | 0.6 | 1.1 | -0.83 |
| neuropathic pain | 2.1 | 0.5 | 3.2 |
| Neuropathy (all types) | 1.1 | 1.5 | -0.36 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.5 | 1.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.4 | 2.4 | 0.83 |
| NonCeliac Gluten Sensitivity | 2.7 | 2.4 | 0.13 |
| Obesity | 7.1 | 5.9 | 0.2 |
| obsessive-compulsive disorder | 3.3 | 2.2 | 0.5 |
| Osteoarthritis | 2.8 | 1.1 | 1.55 |
| Osteoporosis | 2.8 | 1.4 | 1 |
| pancreatic cancer | 0.5 | 0.2 | 1.5 |
| Parkinson's Disease | 4.7 | 5.5 | -0.17 |
| Polycystic ovary syndrome | 4.8 | 4.1 | 0.17 |
| Postural orthostatic tachycardia syndrome | 0.5 | -0.5 | |
| Premenstrual dysphoric disorder | 1.1 | 1.1 | |
| primary biliary cholangitis | 0.8 | 0.2 | 3 |
| Primary sclerosing cholangitis | 4.3 | 0.6 | 6.17 |
| Psoriasis | 2.3 | 2.2 | 0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.5 | 3.3 | 0.36 |
| Rosacea | 1.6 | 0.5 | 2.2 |
| Schizophrenia | 5.1 | 3.4 | 0.5 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 1.7 | 4.3 | -1.53 |
| Sleep Apnea | 1.7 | 1.3 | 0.31 |
| Slow gastric motility / Gastroparesis | 0.5 | 0.5 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.7 | 0.57 |
| Stress / posttraumatic stress disorder | 4.4 | 2.1 | 1.1 |
| Systemic Lupus Erythematosus | 3.7 | 1.6 | 1.31 |
| Tic Disorder | 1.3 | -1.3 | |
| Tourette syndrome | 0.2 | 0.9 | -3.5 |
| Type 1 Diabetes | 2.5 | 4.1 | -0.64 |
| Type 2 Diabetes | 6.4 | 5.6 | 0.14 |
| Ulcerative colitis | 6.7 | 5.7 | 0.18 |
| Unhealthy Ageing | 2.8 | 0.6 | 3.67 |
| Vitiligo | 2.7 | 1.4 | 0.93 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
